- Company
- The outpatient Rx market is shrinking in this winter
- by Chon, Seung-Hyun Mar 18, 2021 06:22am
- With the winter flu season, the outpatient prescription drug market is shrinking. In January and February of this year, the prescription size decreased by 6% from last year. The outpatient prescription drug market has been sluggish since the end of last year. It is analyzed that the prescription drug market has also been affected by a sharp decl
- Company
- Industry to yet again drive for flexible use of ICER
- by Eo, Yun-Ho Mar 18, 2021 06:20am
- The pharmaceutical industry is to push for the versatile use of incremental cost-effectiveness ratio (ICER). Related industry sources reported, a third meeting for the public-private consultative council to improve the drug pricing would be held on Mar. 19. Director Yang Yoon Seok and Deputy Director Choi Kyung-Ho of Pharmaceutical Benefi
- Company
- Chinese regulator cracks down on illegal Botox distribution
- by Nho, Byung Chul Mar 18, 2021 06:19am
- Chinese regulators are expected to strengthen crackdowns on unauthorized procedures in the local medical and beauty market, effectively blocking exports of illegal botulinum toxins to China. According to the Chinese media, Xinhua, etc. on the 15th, the public security authorities said they would strictly crack down on illegal activities r
- Company
- Repurposed drugs for COVID-19 unveil clinical trial findings
- by Moon, sung-ho Mar 18, 2021 06:19am
- A series of clinical trial results in repurposing already-commercialized drugs for COVID-19 treatment is unveiling one by one, and the outcome seems to be contrasting among the pharmaceutical companies. For some pharmaceutical companies, their highly anticipated clinical trials have failed and the results are affecting different drugs by oth
- Company
- Lynparza, to be approved for prostate & pancreatic cancer
- by Eo, Yun-Ho Mar 17, 2021 06:10am
- Lynparza, a PARP inhibitor, is expected to be approved as a treatment for prostate and pancreatic cancer in Korea. According to related industries, AstraZeneca is currently expanding the license to Lynparza (Olaparib) for two indications of maintenance therapy for patients with metastatic castration-resistant prostate cancer with a homolog
- Policy
- Alunbrig coverage granted for first-line lung cancer therapy
- by Lee, Hye-Kyung Mar 17, 2021 06:10am
- The South Korean health authority approved listing Takeda Pharmaceuticals’ Alunbrig (brigatinib) for treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) as first-line therapy, seven months after the indication expansion. The Health Insurance Review and Assessment Service (HIRA) recently published a revised n
- Company
- General hospitals to prescribe Dupixent for adolescents
- by Eo, Yun-Ho Mar 17, 2021 06:10am
- An atopic dermatitis treatment for children and adolescents Dupixent is to be prescribed at general hospitals in South Korea. A related industry source reported Sanofi Genzyme’s atopic dermatitis treatment Dupixent (dupilumab) 200 mg has been passed by drug committees at Seoul National University Hospital, National Medical Center, Korea
- Policy
- PE guideline revised for the first time in 9 years
- by Lee, Hye-Kyung Mar 17, 2021 06:10am
- The pharmacoeconomic evaluation (PE) guideline revised by South Korea’s Health Insurance Review and Assessment Service (HIRA) for the first time in nine years has been in effect from last January. The amended 2021 version of the PE guideline reflects the latest evaluation methodology, and specifies the detailed evaluation criteria based on
- Company
- Yuhan to sell Samsung’s biosimilar for Humira in Korea
- by An, Kyung-Jin Mar 17, 2021 06:09am
- Samsung Bioepis announced on the 15th that it has signed a marketing partnership with Yuhan for domestic sales of Adalloce, biosimilar for Humira. Adalloce is a biosimilar of Adalimuma with the largest global sales. It was the first in Korea to be approved for sale among the biosimilars for Adalimuma. It treats autoimmune diseases such as
- Company
- Praluent is in the process of listing insurance benefits
- by Eo, Yun-Ho Mar 17, 2021 06:09am
- Sanofi-Aventis' PCSK inhibitor Praluent is belatedly in the process of registering insurance benefits. It is slow compared to the rival drug Amgen's Repatha. According to the industry on the 12th, Praluent (Alirocumab) was recently judged appropriate for benefit from the HIRA's Pharmaceutical Benefits Advisory Committee. It is a PCSK9 inhi
